CYP2C19 and cancer: The mechanism behind the decrease of CYP2C19 activity observed in cancer patients may be related to the inflammatory response even though it remains debated (Helsby et al., 2008; Burns et al., 2014; Yasu et al., 2017; Mafuru et al., 2019).